Yield10 Bioscience (YTEN) Stock Price, News & Analysis

Company Overview

Yield10 Bioscience, Inc. is an agricultural bioscience company headquartered in Woburn, Massachusetts, that focuses on improving crop yield and performance through cutting-edge trait discovery and development. The company employs a proprietary platform to identify genes and pathways that control seed yield, oil content and abiotic stress tolerance. By leveraging tools such as gene editing, genomics and metabolic engineering, Yield10 aims to deliver step-change improvements in major row crops including canola, soybean, rice, wheat and corn.

A core element of Yield10’s research strategy is the use of Camelina sativa, a fast-growing oilseed crop, as a model system for trait evaluation. Camelina serves as a rapid testbed for candidate yield genes, allowing the company to advance promising traits more quickly than in larger grain crops. Once traits are validated in Camelina, Yield10 works to translate those improvements into high-value commercial crops through greenhouse and field trials under a range of environmental conditions. The company’s pipeline includes multiple trait development programs aimed at boosting pod number, seed size and seed oil content.

Yield10 supports its discovery and development efforts through collaborations and licensing agreements with leading agribusiness partners. These partnerships provide access to large-scale field trial capabilities and commercial germplasm, accelerating the path to market. Led by a management team of experienced professionals in agricultural biotechnology and crop science, Yield10 conducts research primarily in North America while pursuing global deployment of its technologies through strategic alliances with seed companies and other industry stakeholders.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.0150 to $0.0150
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 78,164 shs
• Market Capitalization: $257 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

YTEN Stock Analysis - Frequently Asked Questions

How were Yield10 Bioscience's earnings last quarter?

Yield10 Bioscience, Inc. (NASDAQ:YTEN) posted its quarterly earnings results on Tuesday, November, 9th. The specialty chemicals company reported ($11.76) EPS for the quarter, beating analysts' consensus estimates of ($15.60) by $3.84. The specialty chemicals company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.22 million.

When did Yield10 Bioscience's stock split?

Yield10 Bioscience shares reverse split on the morning of Friday, May 3rd 2024.The 1-24 reverse split was announced on Friday, May 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Yield10 Bioscience?

Shares of YTEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Yield10 Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Yield10 Bioscience investors own include Canopy Growth (CGC), KUSHCO (KSHB), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE) and FuelCell Energy (FCEL).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 9/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Consumer Staples
• Industry: Agricultural production - crops
• Sub-Industry: Agriculture
• Current Symbol: NASDAQ:YTEN
• CIK: 1121702
• Web: www.yield10bio.com
• Phone: (617) 583-1700
• Fax: 617-583-1768
• Employees: 30
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): ($26.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.45 million
• Net Margins: N/A
• Pretax Margin: -1,693.60%
• Return on Equity: N/A
• Return on Assets: -296.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.16
• Quick Ratio: 0.16

Sales & Book Value

• Annual Sales: $60 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.97) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 734,000
• Free Float: 689,000
• Market Cap: $257 thousand
• Optionable: Not Optionable
• Beta: 1.48